{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"ss-31-glp-1","title":"SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers","body":"## What's breaking down\n\nMitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2+ lb weekly loss, which can include lean mass if protein intake and resistance training lag. Each pound of body weight lost removes roughly 4 lb of compressive force from the spine and joints during daily movement, but the metabolic shift may also increase cellular stress on mitochondria in muscle and other tissues.\n\nSS-31 (elamipretide) is studied for its ability to bind cardiolipin in the inner mitochondrial membrane. This interaction is discussed in preclinical work as supporting electron transport chain efficiency and lowering reactive oxygen species. The article focuses on whether this mitochondrial layer interacts with the metabolic changes seen during GLP-1 use.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial bioenergetics form part of your situation while using GLP-1 agonists, SS-31 is examined because it targets repair at the mitochondrial membrane rather than symptom masking.\n\n1. GLP-1 driven weight loss alters energy demand and substrate use.\n2. Mitochondria in muscle and other tissues may experience increased oxidative load during this transition.\n3. SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin.\n4. Preclinical models show this association correlates with improved ATP production and reduced electron leak.\n5. Therefore, if mitochondrial efficiency is a limiting factor for you during GLP-1 therapy, the peptide is studied for direct membrane stabilization rather than downstream metabolic signaling.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists primarily support metabolism by enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying. This produces sustained caloric deficit and weight reduction. The weight loss itself lowers mechanical load on the musculoskeletal system—approximately 4 lb of lumbar compressive force per pound lost. However, rapid loss can trade off against lean mass preservation if resistance training and protein are insufficient. The drug class does not directly address mitochondrial membrane integrity; any mitochondrial benefit would be indirect through reduced adiposity and improved glycemic control.\n\n## How these fit together\n\nSS-31 addresses the mitochondrial membrane layer. GLP-1 agonists address systemic energy balance and mechanical unloading. In a single-compound focus on SS-31, the two are considered together because mitochondrial repair pathways may complement the metabolic unloading that occurs with GLP-1 use, without overlapping mechanisms.\n\n## What the evidence actually shows\n\nHuman trial data for SS-31 exists in primary mitochondrial myopathy and heart failure populations. One randomized, placebo-controlled trial in adults with primary mitochondrial myopathy reported a dose-dependent increase in 6-minute walk test distance after 5 days of intravenous dosing (Class I evidence for short-term exercise performance). A phase 3 trial (MMPOWER-3) showed mixed genotype-specific results. In heart failure, a 28-day subcutaneous study found the compound well tolerated but did not meet primary efficacy endpoints in all measures.\n\nPreclinical studies (rodent and cell models) consistently demonstrate cardiolipin binding, improved mitochondrial respiration, and reduced ROS. No published human trials examine SS-31 combined with GLP-1 agonists. Evidence inventory: multiple human trials (phase 2/3) for mitochondrial disease indications; dozens of animal studies on mitochondrial function; limited anecdotal reports of concurrent use with GLP-1 compounds on forums.\n\n## What scientists say\n\nResearchers describe SS-31 as selectively localizing to mitochondria and stabilizing cardiolipin to support electron transport chain supercomplexes. Clinical trial summaries note good short-term tolerability with injection-site reactions as the main observation. Long-term human data beyond 28–168 weeks in specific rare-disease cohorts remain limited. No peer-reviewed statements address direct synergy with GLP-1 agonists.\n\n## What people say on Reddit\n\nForum users report trying SS-31 alongside tirzepatide or semaglutide for perceived energy support during weight loss. Some describe subjective improvements in fatigue or skin appearance when stacking with other compounds; others note initial fatigue or GI adjustment symptoms that later subsided. Posts emphasize that SS-31 remains investigational outside approved rare-disease indications and stress sourcing and monitoring concerns.\n\n## What people say on X\n\nPublic posts on X largely mirror forum discussions: users reference ongoing trials, share interest in mitochondrial peptides during GLP-1 therapy, and note the 2025 FDA approval for Barth syndrome. Anecdotal tone dominates; quantitative outcome reports are absent.\n\n## What we do not know\n\nNo human data exist on combined SS-31 and GLP-1 agonist protocols. Long-term safety beyond approved indications is not established. Effects on muscle preservation during GLP-1 weight loss remain untested. Optimal sequencing or duration for any potential mitochondrial support layer is unknown.\n\n## Safety and limits\n\nIn published trials, SS-31 was generally well tolerated. Most common observations were mild injection-site reactions (erythema, pruritus). Occasional reports mention headache or dizziness. No serious adverse events were linked to the peptide in the reviewed studies. Because human combination data with GLP-1 agonists are absent, any interaction profile is unknown. The compound holds FDA approval only for specific rare mitochondrial disease; use outside those indications is off-label and investigational.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ss-31-glp-1/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"SS-31 binds cardiolipin in the inner mitochondrial membrane and is associated with improved electron transport efficiency in preclinical models.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s14"],"source_status":"sourced","why_material":"Establishes core mechanism discussed for mitochondrial repair layer.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A randomized placebo-controlled trial in primary mitochondrial myopathy patients showed dose-dependent improvement in 6-minute walk distance after 5 days of IV SS-31 (Class I evidence).","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Direct human efficacy signal for exercise performance.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GLP-1 agonists produce weight loss that mechanically unloads the spine and joints by approximately 4 lb compressive force per pound lost.","section":"Why GLP-1 agonists (class) matters for you","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Standard biomechanical relationship used to frame load reduction benefit.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human trials examine concurrent SS-31 and GLP-1 agonist use.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gap for the specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"FDA granted accelerated approval to elamipretide (SS-31) for Barth syndrome in 2025 based on TAZPOWER trial data.","section":"What the evidence actually shows","tier":"human","source_ids":["s19"],"source_status":"sourced","why_material":"Current regulatory status as of 2026.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users report subjective energy or fatigue changes when using SS-31 alongside tirzepatide; reports are anecdotal and mixed.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s10"],"source_status":"sourced","why_material":"Documents real-world discussion of the combination.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/","title":"Mitochondrial protein interaction landscape of SS-31","quote":"The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown.","summary":"Identifies SS-31 interactors linked to ATP production and 2-oxoglutarate metabolism.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:55:00.209Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"942b2c42e49f0f647400e1758e9acab4cf4ac56269bb1610b02a376e5e02936b"},{"id":"s5","type":"pubmed","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000005255","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","quote":"Participants who received the highest dose of elamipretide walked a mean of 64.5 m farther at day 5 compared to a change of 20.4 m in the placebo group (p = 0.053).","summary":"Class I evidence for short-term exercise improvement in PMM patients.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:55:00.209Z","link_status":"ok","quote_status":"unverified","prev":"942b2c42e49f0f647400e1758e9acab4cf4ac56269bb1610b02a376e5e02936b","hash":"2315a846a52abfcf91034b65a4cb87902cf2ef102f30f59243e6c642b67ccc7d"},{"id":"s19","type":"news","url":"https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/","title":"FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31","quote":"The recent FDA approval of elamipretide is for the treatment of a rare disease...","summary":"Reports 2025 FDA approval for Barth syndrome.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:55:00.209Z","link_status":"ok","quote_status":"unverified","prev":"2315a846a52abfcf91034b65a4cb87902cf2ef102f30f59243e6c642b67ccc7d","hash":"8ad2641afe4c0f0ca27e85a3dfb7a77b5e07efdd00d8d1f182996b2a59b9e978"},{"id":"s10","type":"reddit","url":"https://www.reddit.com/r/compoundedtirzepatide/comments/1scbh7n/anyone_here_taking_other_peptides_along_with/","title":"Anyone here taking other peptides along with tirzepatide?","quote":"I do feel like I get a little energy boost from the 5Amino/ ss-31...","summary":"Anecdotal report of SS-31 with tirzepatide.","claim_ids":["c6"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:55:00.209Z","link_status":"ok","quote_status":"unverified","prev":"8ad2641afe4c0f0ca27e85a3dfb7a77b5e07efdd00d8d1f182996b2a59b9e978","hash":"a25b289ab77277297d3eecf0fac62c4eeaa3908ad5aa06572b7150444f6b27ab"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:55:00.909Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers","register":"source_ledger","body":"## What's breaking down\n\nMitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2+ lb weekly loss, which can include lean mass if protein intake and resistance training lag. Each pound of body weight lost removes roughly 4 lb of compressive force from the spine and joints during daily movement, but the metabolic shift may also increase cellular stress on mitochondria in muscle and other tissues.\n\nSS-31 (elamipretide) is studied for its ability to bind cardiolipin in the inner mitochondrial membrane. This interaction is discussed in preclinical work as supporting electron transport chain efficiency and lowering reactive oxygen species. The article focuses on whether this mitochondrial layer interacts with the metabolic changes seen during GLP-1 use.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial bioenergetics form part of your situation while using GLP-1 agonists, SS-31 is examined because it targets repair at the mitochondrial membrane rather than symptom masking.\n\n1. GLP-1 driven weight loss alters energy demand and substrate use.\n2. Mitochondria in muscle and other tissues may experience increased oxidative load during this transition.\n3. SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin.\n4. Preclinical models show this association correlates with improved ATP production and reduced electron leak.\n5. Therefore, if mitochondrial efficiency is a limiting factor for you during GLP-1 therapy, the peptide is studied for direct membrane stabilization rather than downstream metabolic signaling.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists primarily support metabolism by enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying. This produces sustained caloric deficit and weight reduction. The weight loss itself lowers mechanical load on the musculoskeletal system—approximately 4 lb of lumbar compressive force per pound lost. However, rapid loss can trade off against lean mass preservation if resistance training and protein are insufficient. The drug class does not directly address mitochondrial membrane integrity; any mitochondrial benefit would be indirect through reduced adiposity and improved glycemic control.\n\n## How these fit together\n\nSS-31 addresses the mitochondrial membrane layer. GLP-1 agonists address systemic energy balance and mechanical unloading. In a single-compound focus on SS-31, the two are considered together because mitochondrial repair pathways may complement the metabolic unloading that occurs with GLP-1 use, without overlapping mechanisms.\n\n## What the evidence actually shows\n\nHuman trial data for SS-31 exists in primary mitochondrial myopathy and heart failure populations. One randomized, placebo-controlled trial in adults with primary mitochondrial myopathy reported a dose-dependent increase in 6-minute walk test distance after 5 days of intravenous dosing (Class I evidence for short-term exercise performance). A phase 3 trial (MMPOWER-3) showed mixed genotype-specific results. In heart failure, a 28-day subcutaneous study found the compound well tolerated but did not meet primary efficacy endpoints in all measures.\n\nPreclinical studies (rodent and cell models) consistently demonstrate cardiolipin binding, improved mitochondrial respiration, and reduced ROS. No published human trials examine SS-31 combined with GLP-1 agonists. Evidence inventory: multiple human trials (phase 2/3) for mitochondrial disease indications; dozens of animal studies on mitochondrial function; limited anecdotal reports of concurrent use with GLP-1 compounds on forums.\n\n## What scientists say\n\nResearchers describe SS-31 as selectively localizing to mitochondria and stabilizing cardiolipin to support electron transport chain supercomplexes. Clinical trial summaries note good short-term tolerability with injection-site reactions as the main observation. Long-term human data beyond 28–168 weeks in specific rare-disease cohorts remain limited. No peer-reviewed statements address direct synergy with GLP-1 agonists.\n\n## What people say on Reddit\n\nForum users report trying SS-31 alongside tirzepatide or semaglutide for perceived energy support during weight loss. Some describe subjective improvements in fatigue or skin appearance when stacking with other compounds; others note initial fatigue or GI adjustment symptoms that later subsided. Posts emphasize that SS-31 remains investigational outside approved rare-disease indications and stress sourcing and monitoring concerns.\n\n## What people say on X\n\nPublic posts on X largely mirror forum discussions: users reference ongoing trials, share interest in mitochondrial peptides during GLP-1 therapy, and note the 2025 FDA approval for Barth syndrome. Anecdotal tone dominates; quantitative outcome reports are absent.\n\n## What we do not know\n\nNo human data exist on combined SS-31 and GLP-1 agonist protocols. Long-term safety beyond approved indications is not established. Effects on muscle preservation during GLP-1 weight loss remain untested. Optimal sequencing or duration for any potential mitochondrial support layer is unknown.\n\n## Safety and limits\n\nIn published trials, SS-31 was generally well tolerated. Most common observations were mild injection-site reactions (erythema, pruritus). Occasional reports mention headache or dizziness. No serious adverse events were linked to the peptide in the reviewed studies. Because human combination data with GLP-1 agonists are absent, any interaction profile is unknown. The compound holds FDA approval only for specific rare mitochondrial disease; use outside those indications is off-label and investigational.","claims":[{"id":"c1","text":"SS-31 binds cardiolipin in the inner mitochondrial membrane and is associated with improved electron transport efficiency in preclinical models.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s14"],"source_status":"sourced","why_material":"Establishes core mechanism discussed for mitochondrial repair layer.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A randomized placebo-controlled trial in primary mitochondrial myopathy patients showed dose-dependent improvement in 6-minute walk distance after 5 days of IV SS-31 (Class I evidence).","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Direct human efficacy signal for exercise performance.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GLP-1 agonists produce weight loss that mechanically unloads the spine and joints by approximately 4 lb compressive force per pound lost.","section":"Why GLP-1 agonists (class) matters for you","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Standard biomechanical relationship used to frame load reduction benefit.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human trials examine concurrent SS-31 and GLP-1 agonist use.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gap for the specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"FDA granted accelerated approval to elamipretide (SS-31) for Barth syndrome in 2025 based on TAZPOWER trial data.","section":"What the evidence actually shows","tier":"human","source_ids":["s19"],"source_status":"sourced","why_material":"Current regulatory status as of 2026.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users report subjective energy or fatigue changes when using SS-31 alongside tirzepatide; reports are anecdotal and mixed.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s10"],"source_status":"sourced","why_material":"Documents real-world discussion of the combination.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/","title":"Mitochondrial protein interaction landscape of SS-31","quote":"The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"pubmed","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000005255","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","quote":"Participants who received the highest dose of elamipretide walked a mean of 64.5 m farther at day 5 compared to a change of 20.4 m in the placebo group (p = 0.053).","link_status":"ok","quote_status":"unverified"},{"id":"s19","type":"news","url":"https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/","title":"FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31","quote":"The recent FDA approval of elamipretide is for the treatment of a rare disease...","link_status":"ok","quote_status":"unverified"},{"id":"s10","type":"reddit","url":"https://www.reddit.com/r/compoundedtirzepatide/comments/1scbh7n/anyone_here_taking_other_peptides_along_with/","title":"Anyone here taking other peptides along with tirzepatide?","quote":"I do feel like I get a little energy boost from the 5Amino/ ss-31...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":16822,"tokens_out":3169,"cost":0.02895,"prev_hash":"genesis","hash":"e632b8a1ef66c942b4d0d76d6969317de15c0db29b194aeda758c2356b5f8501"}],"provenance":[{"ts":"2026-06-29T23:55:00.909Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Glp 1\nSlug: ss-31-glp-1\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 agonists (class)\",\"**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\",\"**Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**, or **supports metabolism** — and whether that helps or trades off repair for your condition.\"],\"prose\":\"1. **Drug:** GLP-1 agonists (class)\\n2. **What it does:** Metabolic benefit vs gut slowing / muscle loss","response":"{\n  \"slug\": \"ss-31-glp-1\",\n  \"title\": \"SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers\",\n  \"body\": \"## What's breaking down\\n\\nMitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2+ lb weekly loss, which can include lean mass if protein intake and resistance training lag. Each pound of body weight lost removes roughly 4 lb of compressive force from the spine and joints during daily movement, but the metabolic shift may also increase cellular stress on mitochondria in muscle and other tissues.\\n\\nSS-31 (elamipretide) is studied for its ability to bind cardiolipin in the inner mitochondrial membrane. This interaction is discussed in preclinical work as supporting electron transport chain efficiency and lowering reactive oxygen species. The article focuses on whether this mitochondrial layer interacts with the metabolic changes seen during GLP-1 use.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial bioenergetics form part of your situation while using GLP-1 agonists, SS-31 is examined because it targets repair at the mitochondrial membrane rather than symptom masking.\\n\\n1. GLP-1 driven weight loss alters energy demand and substrate use.\\n2. Mitochondria in muscle and other tissues may experience increased oxidative load during this transition.\\n3. SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin.\\n4. Preclinical models show this association correlates with improved ATP production and reduced electron leak.\\n5. Therefore, if mitochondrial efficiency is a limiting factor for you during GLP-1 therapy, the peptide is studied for direct membrane stabilization rather than downstream metabolic signaling.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\nGLP-1 agonists primarily support metabolism by enhancing insulin secre","tokens_in":16822,"tokens_out":3169,"cost":0,"prev":"genesis","hash":"b87817cb8e5059cccfd97de54c43ac8e324a2d6052fe5c7a99d78446c55fb156"},{"ts":"2026-07-17T02:42:03.325Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-glp-1","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b87817cb8e5059cccfd97de54c43ac8e324a2d6052fe5c7a99d78446c55fb156","hash":"5339d8ba65011c316cae670bddc828ac77b16f9fca27114280405e7523ee1738"}],"energy":{"passes":2,"tokens_in":16822,"tokens_out":3169,"tokens_total":19991,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5339d8ba65011c316cae670bddc828ac77b16f9fca27114280405e7523ee1738"},"posted_at":"2026-06-29T21:33:21.949Z","created_at":"2026-06-29T21:33:21.949Z","updated_at":"2026-07-17T02:42:03.325Z","machine":{"shape":"article.machine/v1","slug":"ss-31-glp-1","kind":"article","read":{"human":"https://miscsubjects.com/a/ss-31-glp-1","json":"https://miscsubjects.com/api/articles/ss-31-glp-1","bundle":"https://miscsubjects.com/api/articles/ss-31-glp-1/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/ss-31-glp-1/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ss-31-glp-1","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-glp-1\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-glp-1\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ss-31-glp-1/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ss-31-glp-1\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ss-31-glp-1 | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ss-31-glp-1","json":"/api/articles/ss-31-glp-1","markdown":"/api/articles/ss-31-glp-1/bundle?format=markdown","skill":"/api/articles/ss-31-glp-1/skill","topology":"/api/articles/ss-31-glp-1/topology","versions":"/api/articles/ss-31-glp-1/revisions","invocations":"/api/articles/ss-31-glp-1/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ss-31-glp-1","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"e83414d2d078ec0fd29f7bd419048ed49b98cee30844a6c15d835a379ad95f79","object":{"object_type":"article-object","identity":{"id":"article:ss-31-glp-1","slug":"ss-31-glp-1","title":"SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/ss-31-glp-1","role":"explain","audience":"human"},"skill":{"route":"/api/articles/ss-31-glp-1/skill","role":"direct behavior","audience":"model","content":"---\nname: ss-31-glp-1\ndescription: Apply the SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers\n\nThis Skill is the behavioral expression of [the canonical article](/a/ss-31-glp-1). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/ss-31-glp-1.\n- Read claims and relationships at /api/articles/ss-31-glp-1/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Mitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2\n\n## Representations\n\n- Human: /a/ss-31-glp-1\n- JSON: /api/articles/ss-31-glp-1\n- Relationships: /api/articles/ss-31-glp-1/topology\n- History: /api/articles/ss-31-glp-1/revisions\n"},"json":{"route":"/api/articles/ss-31-glp-1","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/ss-31-glp-1/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","ss","31","glp","1"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/ss-31-glp-1/invocations?status=success","failure_events":"/api/articles/ss-31-glp-1/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"ss-31-glp-1","title":"SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers","body":"## What's breaking down\n\nMitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2+ lb weekly loss, which can include lean mass if protein intake and resistance training lag. Each pound of body weight lost removes roughly 4 lb of compressive force from the spine and joints during daily movement, but the metabolic shift may also increase cellular stress on mitochondria in muscle and other tissues.\n\nSS-31 (elamipretide) is studied for its ability to bind cardiolipin in the inner mitochondrial membrane. This interaction is discussed in preclinical work as supporting electron transport chain efficiency and lowering reactive oxygen species. The article focuses on whether this mitochondrial layer interacts with the metabolic changes seen during GLP-1 use.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial bioenergetics form part of your situation while using GLP-1 agonists, SS-31 is examined because it targets repair at the mitochondrial membrane rather than symptom masking.\n\n1. GLP-1 driven weight loss alters energy demand and substrate use.\n2. Mitochondria in muscle and other tissues may experience increased oxidative load during this transition.\n3. SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin.\n4. Preclinical models show this association correlates with improved ATP production and reduced electron leak.\n5. Therefore, if mitochondrial efficiency is a limiting factor for you during GLP-1 therapy, the peptide is studied for direct membrane stabilization rather than downstream metabolic signaling.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists primarily support metabolism by enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying. This produces sustained caloric deficit and weight reduction. The weight loss itself lowers mechanical load on the musculoskeletal system—approximately 4 lb of lumbar compressive force per pound lost. However, rapid loss can trade off against lean mass preservation if resistance training and protein are insufficient. The drug class does not directly address mitochondrial membrane integrity; any mitochondrial benefit would be indirect through reduced adiposity and improved glycemic control.\n\n## How these fit together\n\nSS-31 addresses the mitochondrial membrane layer. GLP-1 agonists address systemic energy balance and mechanical unloading. In a single-compound focus on SS-31, the two are considered together because mitochondrial repair pathways may complement the metabolic unloading that occurs with GLP-1 use, without overlapping mechanisms.\n\n## What the evidence actually shows\n\nHuman trial data for SS-31 exists in primary mitochondrial myopathy and heart failure populations. One randomized, placebo-controlled trial in adults with primary mitochondrial myopathy reported a dose-dependent increase in 6-minute walk test distance after 5 days of intravenous dosing (Class I evidence for short-term exercise performance). A phase 3 trial (MMPOWER-3) showed mixed genotype-specific results. In heart failure, a 28-day subcutaneous study found the compound well tolerated but did not meet primary efficacy endpoints in all measures.\n\nPreclinical studies (rodent and cell models) consistently demonstrate cardiolipin binding, improved mitochondrial respiration, and reduced ROS. No published human trials examine SS-31 combined with GLP-1 agonists. Evidence inventory: multiple human trials (phase 2/3) for mitochondrial disease indications; dozens of animal studies on mitochondrial function; limited anecdotal reports of concurrent use with GLP-1 compounds on forums.\n\n## What scientists say\n\nResearchers describe SS-31 as selectively localizing to mitochondria and stabilizing cardiolipin to support electron transport chain supercomplexes. Clinical trial summaries note good short-term tolerability with injection-site reactions as the main observation. Long-term human data beyond 28–168 weeks in specific rare-disease cohorts remain limited. No peer-reviewed statements address direct synergy with GLP-1 agonists.\n\n## What people say on Reddit\n\nForum users report trying SS-31 alongside tirzepatide or semaglutide for perceived energy support during weight loss. Some describe subjective improvements in fatigue or skin appearance when stacking with other compounds; others note initial fatigue or GI adjustment symptoms that later subsided. Posts emphasize that SS-31 remains investigational outside approved rare-disease indications and stress sourcing and monitoring concerns.\n\n## What people say on X\n\nPublic posts on X largely mirror forum discussions: users reference ongoing trials, share interest in mitochondrial peptides during GLP-1 therapy, and note the 2025 FDA approval for Barth syndrome. Anecdotal tone dominates; quantitative outcome reports are absent.\n\n## What we do not know\n\nNo human data exist on combined SS-31 and GLP-1 agonist protocols. Long-term safety beyond approved indications is not established. Effects on muscle preservation during GLP-1 weight loss remain untested. Optimal sequencing or duration for any potential mitochondrial support layer is unknown.\n\n## Safety and limits\n\nIn published trials, SS-31 was generally well tolerated. Most common observations were mild injection-site reactions (erythema, pruritus). Occasional reports mention headache or dizziness. No serious adverse events were linked to the peptide in the reviewed studies. Because human combination data with GLP-1 agonists are absent, any interaction profile is unknown. The compound holds FDA approval only for specific rare mitochondrial disease; use outside those indications is off-label and investigational.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ss-31-glp-1/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"SS-31 binds cardiolipin in the inner mitochondrial membrane and is associated with improved electron transport efficiency in preclinical models.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s14"],"source_status":"sourced","why_material":"Establishes core mechanism discussed for mitochondrial repair layer.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A randomized placebo-controlled trial in primary mitochondrial myopathy patients showed dose-dependent improvement in 6-minute walk distance after 5 days of IV SS-31 (Class I evidence).","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Direct human efficacy signal for exercise performance.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GLP-1 agonists produce weight loss that mechanically unloads the spine and joints by approximately 4 lb compressive force per pound lost.","section":"Why GLP-1 agonists (class) matters for you","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Standard biomechanical relationship used to frame load reduction benefit.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human trials examine concurrent SS-31 and GLP-1 agonist use.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gap for the specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"FDA granted accelerated approval to elamipretide (SS-31) for Barth syndrome in 2025 based on TAZPOWER trial data.","section":"What the evidence actually shows","tier":"human","source_ids":["s19"],"source_status":"sourced","why_material":"Current regulatory status as of 2026.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users report subjective energy or fatigue changes when using SS-31 alongside tirzepatide; reports are anecdotal and mixed.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s10"],"source_status":"sourced","why_material":"Documents real-world discussion of the combination.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/","title":"Mitochondrial protein interaction landscape of SS-31","quote":"The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown.","summary":"Identifies SS-31 interactors linked to ATP production and 2-oxoglutarate metabolism.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:55:00.209Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"942b2c42e49f0f647400e1758e9acab4cf4ac56269bb1610b02a376e5e02936b"},{"id":"s5","type":"pubmed","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000005255","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","quote":"Participants who received the highest dose of elamipretide walked a mean of 64.5 m farther at day 5 compared to a change of 20.4 m in the placebo group (p = 0.053).","summary":"Class I evidence for short-term exercise improvement in PMM patients.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:55:00.209Z","link_status":"ok","quote_status":"unverified","prev":"942b2c42e49f0f647400e1758e9acab4cf4ac56269bb1610b02a376e5e02936b","hash":"2315a846a52abfcf91034b65a4cb87902cf2ef102f30f59243e6c642b67ccc7d"},{"id":"s19","type":"news","url":"https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/","title":"FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31","quote":"The recent FDA approval of elamipretide is for the treatment of a rare disease...","summary":"Reports 2025 FDA approval for Barth syndrome.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:55:00.209Z","link_status":"ok","quote_status":"unverified","prev":"2315a846a52abfcf91034b65a4cb87902cf2ef102f30f59243e6c642b67ccc7d","hash":"8ad2641afe4c0f0ca27e85a3dfb7a77b5e07efdd00d8d1f182996b2a59b9e978"},{"id":"s10","type":"reddit","url":"https://www.reddit.com/r/compoundedtirzepatide/comments/1scbh7n/anyone_here_taking_other_peptides_along_with/","title":"Anyone here taking other peptides along with tirzepatide?","quote":"I do feel like I get a little energy boost from the 5Amino/ ss-31...","summary":"Anecdotal report of SS-31 with tirzepatide.","claim_ids":["c6"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:55:00.209Z","link_status":"ok","quote_status":"unverified","prev":"8ad2641afe4c0f0ca27e85a3dfb7a77b5e07efdd00d8d1f182996b2a59b9e978","hash":"a25b289ab77277297d3eecf0fac62c4eeaa3908ad5aa06572b7150444f6b27ab"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:55:00.909Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers","register":"source_ledger","body":"## What's breaking down\n\nMitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2+ lb weekly loss, which can include lean mass if protein intake and resistance training lag. Each pound of body weight lost removes roughly 4 lb of compressive force from the spine and joints during daily movement, but the metabolic shift may also increase cellular stress on mitochondria in muscle and other tissues.\n\nSS-31 (elamipretide) is studied for its ability to bind cardiolipin in the inner mitochondrial membrane. This interaction is discussed in preclinical work as supporting electron transport chain efficiency and lowering reactive oxygen species. The article focuses on whether this mitochondrial layer interacts with the metabolic changes seen during GLP-1 use.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial bioenergetics form part of your situation while using GLP-1 agonists, SS-31 is examined because it targets repair at the mitochondrial membrane rather than symptom masking.\n\n1. GLP-1 driven weight loss alters energy demand and substrate use.\n2. Mitochondria in muscle and other tissues may experience increased oxidative load during this transition.\n3. SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin.\n4. Preclinical models show this association correlates with improved ATP production and reduced electron leak.\n5. Therefore, if mitochondrial efficiency is a limiting factor for you during GLP-1 therapy, the peptide is studied for direct membrane stabilization rather than downstream metabolic signaling.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists primarily support metabolism by enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying. This produces sustained caloric deficit and weight reduction. The weight loss itself lowers mechanical load on the musculoskeletal system—approximately 4 lb of lumbar compressive force per pound lost. However, rapid loss can trade off against lean mass preservation if resistance training and protein are insufficient. The drug class does not directly address mitochondrial membrane integrity; any mitochondrial benefit would be indirect through reduced adiposity and improved glycemic control.\n\n## How these fit together\n\nSS-31 addresses the mitochondrial membrane layer. GLP-1 agonists address systemic energy balance and mechanical unloading. In a single-compound focus on SS-31, the two are considered together because mitochondrial repair pathways may complement the metabolic unloading that occurs with GLP-1 use, without overlapping mechanisms.\n\n## What the evidence actually shows\n\nHuman trial data for SS-31 exists in primary mitochondrial myopathy and heart failure populations. One randomized, placebo-controlled trial in adults with primary mitochondrial myopathy reported a dose-dependent increase in 6-minute walk test distance after 5 days of intravenous dosing (Class I evidence for short-term exercise performance). A phase 3 trial (MMPOWER-3) showed mixed genotype-specific results. In heart failure, a 28-day subcutaneous study found the compound well tolerated but did not meet primary efficacy endpoints in all measures.\n\nPreclinical studies (rodent and cell models) consistently demonstrate cardiolipin binding, improved mitochondrial respiration, and reduced ROS. No published human trials examine SS-31 combined with GLP-1 agonists. Evidence inventory: multiple human trials (phase 2/3) for mitochondrial disease indications; dozens of animal studies on mitochondrial function; limited anecdotal reports of concurrent use with GLP-1 compounds on forums.\n\n## What scientists say\n\nResearchers describe SS-31 as selectively localizing to mitochondria and stabilizing cardiolipin to support electron transport chain supercomplexes. Clinical trial summaries note good short-term tolerability with injection-site reactions as the main observation. Long-term human data beyond 28–168 weeks in specific rare-disease cohorts remain limited. No peer-reviewed statements address direct synergy with GLP-1 agonists.\n\n## What people say on Reddit\n\nForum users report trying SS-31 alongside tirzepatide or semaglutide for perceived energy support during weight loss. Some describe subjective improvements in fatigue or skin appearance when stacking with other compounds; others note initial fatigue or GI adjustment symptoms that later subsided. Posts emphasize that SS-31 remains investigational outside approved rare-disease indications and stress sourcing and monitoring concerns.\n\n## What people say on X\n\nPublic posts on X largely mirror forum discussions: users reference ongoing trials, share interest in mitochondrial peptides during GLP-1 therapy, and note the 2025 FDA approval for Barth syndrome. Anecdotal tone dominates; quantitative outcome reports are absent.\n\n## What we do not know\n\nNo human data exist on combined SS-31 and GLP-1 agonist protocols. Long-term safety beyond approved indications is not established. Effects on muscle preservation during GLP-1 weight loss remain untested. Optimal sequencing or duration for any potential mitochondrial support layer is unknown.\n\n## Safety and limits\n\nIn published trials, SS-31 was generally well tolerated. Most common observations were mild injection-site reactions (erythema, pruritus). Occasional reports mention headache or dizziness. No serious adverse events were linked to the peptide in the reviewed studies. Because human combination data with GLP-1 agonists are absent, any interaction profile is unknown. The compound holds FDA approval only for specific rare mitochondrial disease; use outside those indications is off-label and investigational.","claims":[{"id":"c1","text":"SS-31 binds cardiolipin in the inner mitochondrial membrane and is associated with improved electron transport efficiency in preclinical models.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s14"],"source_status":"sourced","why_material":"Establishes core mechanism discussed for mitochondrial repair layer.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A randomized placebo-controlled trial in primary mitochondrial myopathy patients showed dose-dependent improvement in 6-minute walk distance after 5 days of IV SS-31 (Class I evidence).","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Direct human efficacy signal for exercise performance.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GLP-1 agonists produce weight loss that mechanically unloads the spine and joints by approximately 4 lb compressive force per pound lost.","section":"Why GLP-1 agonists (class) matters for you","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Standard biomechanical relationship used to frame load reduction benefit.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human trials examine concurrent SS-31 and GLP-1 agonist use.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gap for the specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"FDA granted accelerated approval to elamipretide (SS-31) for Barth syndrome in 2025 based on TAZPOWER trial data.","section":"What the evidence actually shows","tier":"human","source_ids":["s19"],"source_status":"sourced","why_material":"Current regulatory status as of 2026.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users report subjective energy or fatigue changes when using SS-31 alongside tirzepatide; reports are anecdotal and mixed.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s10"],"source_status":"sourced","why_material":"Documents real-world discussion of the combination.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:55:00.533Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/","title":"Mitochondrial protein interaction landscape of SS-31","quote":"The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"pubmed","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000005255","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","quote":"Participants who received the highest dose of elamipretide walked a mean of 64.5 m farther at day 5 compared to a change of 20.4 m in the placebo group (p = 0.053).","link_status":"ok","quote_status":"unverified"},{"id":"s19","type":"news","url":"https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/","title":"FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31","quote":"The recent FDA approval of elamipretide is for the treatment of a rare disease...","link_status":"ok","quote_status":"unverified"},{"id":"s10","type":"reddit","url":"https://www.reddit.com/r/compoundedtirzepatide/comments/1scbh7n/anyone_here_taking_other_peptides_along_with/","title":"Anyone here taking other peptides along with tirzepatide?","quote":"I do feel like I get a little energy boost from the 5Amino/ ss-31...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":16822,"tokens_out":3169,"cost":0.02895,"prev_hash":"genesis","hash":"e632b8a1ef66c942b4d0d76d6969317de15c0db29b194aeda758c2356b5f8501"}],"provenance":[{"ts":"2026-06-29T23:55:00.909Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Glp 1\nSlug: ss-31-glp-1\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 agonists (class)\",\"**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\",\"**Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**, or **supports metabolism** — and whether that helps or trades off repair for your condition.\"],\"prose\":\"1. **Drug:** GLP-1 agonists (class)\\n2. **What it does:** Metabolic benefit vs gut slowing / muscle loss","response":"{\n  \"slug\": \"ss-31-glp-1\",\n  \"title\": \"SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers\",\n  \"body\": \"## What's breaking down\\n\\nMitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2+ lb weekly loss, which can include lean mass if protein intake and resistance training lag. Each pound of body weight lost removes roughly 4 lb of compressive force from the spine and joints during daily movement, but the metabolic shift may also increase cellular stress on mitochondria in muscle and other tissues.\\n\\nSS-31 (elamipretide) is studied for its ability to bind cardiolipin in the inner mitochondrial membrane. This interaction is discussed in preclinical work as supporting electron transport chain efficiency and lowering reactive oxygen species. The article focuses on whether this mitochondrial layer interacts with the metabolic changes seen during GLP-1 use.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial bioenergetics form part of your situation while using GLP-1 agonists, SS-31 is examined because it targets repair at the mitochondrial membrane rather than symptom masking.\\n\\n1. GLP-1 driven weight loss alters energy demand and substrate use.\\n2. Mitochondria in muscle and other tissues may experience increased oxidative load during this transition.\\n3. SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin.\\n4. Preclinical models show this association correlates with improved ATP production and reduced electron leak.\\n5. Therefore, if mitochondrial efficiency is a limiting factor for you during GLP-1 therapy, the peptide is studied for direct membrane stabilization rather than downstream metabolic signaling.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\nGLP-1 agonists primarily support metabolism by enhancing insulin secre","tokens_in":16822,"tokens_out":3169,"cost":0,"prev":"genesis","hash":"b87817cb8e5059cccfd97de54c43ac8e324a2d6052fe5c7a99d78446c55fb156"},{"ts":"2026-07-17T02:42:03.325Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-glp-1","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b87817cb8e5059cccfd97de54c43ac8e324a2d6052fe5c7a99d78446c55fb156","hash":"5339d8ba65011c316cae670bddc828ac77b16f9fca27114280405e7523ee1738"}],"energy":{"passes":2,"tokens_in":16822,"tokens_out":3169,"tokens_total":19991,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5339d8ba65011c316cae670bddc828ac77b16f9fca27114280405e7523ee1738"},"posted_at":"2026-06-29T21:33:21.949Z","created_at":"2026-06-29T21:33:21.949Z","updated_at":"2026-07-17T02:42:03.325Z","machine":{"shape":"article.machine/v1","slug":"ss-31-glp-1","kind":"article","read":{"human":"https://miscsubjects.com/a/ss-31-glp-1","json":"https://miscsubjects.com/api/articles/ss-31-glp-1","bundle":"https://miscsubjects.com/api/articles/ss-31-glp-1/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/ss-31-glp-1/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ss-31-glp-1","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-glp-1\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-glp-1\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ss-31-glp-1/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ss-31-glp-1\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ss-31-glp-1 | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ss-31-glp-1","json":"/api/articles/ss-31-glp-1","markdown":"/api/articles/ss-31-glp-1/bundle?format=markdown","skill":"/api/articles/ss-31-glp-1/skill","topology":"/api/articles/ss-31-glp-1/topology","versions":"/api/articles/ss-31-glp-1/revisions","invocations":"/api/articles/ss-31-glp-1/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ss-31-glp-1","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"e83414d2d078ec0fd29f7bd419048ed49b98cee30844a6c15d835a379ad95f79"}}}